Subjects
Healthy Korean male subjects aged 19-45 years with a body mass index of
18-27 kg/m2 were enrolled. They were defined by their
previous medical and surgical history, physical examination, vital
signs, 12-lead electrocardiography (ECG), and clinical laboratory tests.
Those that had been exposed to any investigational products within 90
days prior to the first dosing in the study and those known to be
hypersensitive to evogliptin or glimepiride, were excluded. All subjects
provided a signed informed consent form before any study related
procedure was performed.